435.01

1.13% -4.99

After Hours: 435.01

Madrigal Pharmaceuticals Inc (MDGL)

Overview News Price History Option Chain Financials Why MDGL Down? Discussions Forecast Stock Split

Madrigal Pharmaceuticals Inc stock is traded at $435.01, with a volume of 656.09K. It is down -1.13% in the last 24 hours and down -9.46% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Previous Close:

$440.00

Open:

$440

24h Volume:

656.09K

Relative Volume:

1.91

Market Cap:

$9.88B

Revenue:

Net Income/Loss:

$-518.67M

P/E Ratio:

-17.32

EPS:

-25.12

Net Cash Flow:

$-438.32M

1W Performance:

-11.49%

1M Performance:

-9.46%

6M Performance:

+5.53%

1Y Performance:

+40.56%

1-Day Range:

$434.67

$447.00

1-Week Range:

$424.20

$461.98

52-Week Range:

$265.00

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name

Madrigal Pharmaceuticals Inc

Sector

Healthcare (1108)

Industry

Biotechnology (621)

Phone

404-380-9263

Address

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Employee

528

Twitter

@MadrigalPharma

Next Earnings Date

2024-10-31

Latest SEC Filings

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MDGL Madrigal Pharmaceuticals Inc	435.01	9.99B	0	-518.67M	-438.32M	-25.12
VRTX Vertex Pharmaceuticals Inc	483.05	123.82B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	784.28	81.64B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	816.95	52.00B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	327.36	44.14B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	352.23	40.83B	4.98B	69.60M	525.67M	0.5198

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Initiated	Barclays	Overweight
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-05-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-03-25	Upgrade	BofA Securities	Underperform → Neutral
Oct-15-25	Initiated	Truist	Buy
Sep-04-25	Resumed	H.C. Wainwright	Buy
Feb-28-25	Upgrade	B. Riley Securities	Neutral → Buy
Feb-27-25	Reiterated	H.C. Wainwright	Buy
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform
Apr-22-24	Initiated	BofA Securities	Underperform
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral
Mar-06-24	Initiated	Citigroup	Buy
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell
Dec-20-22	Reiterated	Oppenheimer	Outperform
Dec-19-22	Reiterated	H.C. Wainwright	Buy
Dec-19-22	Reiterated	Piper Sandler	Overweight
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy
Nov-24-20	Resumed	Evercore ISI	Outperform
Nov-06-20	Reiterated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-05-20	Initiated	BMO Capital Markets	Market Perform
May-05-20	Initiated	Chardan Capital Markets	Buy
Jan-30-20	Initiated	Canaccord Genuity	Buy
Jan-09-20	Upgrade	UBS	Neutral → Buy
Nov-07-19	Reiterated	H.C. Wainwright	Buy
Jun-25-19	Initiated	Stifel	Hold
Jun-10-19	Upgrade	B. Riley FBR	Neutral → Buy
Feb-28-19	Reiterated	H.C. Wainwright	Buy
Feb-22-19	Initiated	SVB Leerink	Outperform
Jan-23-19	Initiated	UBS	Neutral
Dec-14-18	Initiated	Wolfe Research	Outperform
Dec-12-18	Initiated	B. Riley FBR	Neutral
Nov-19-18	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-16-18	Upgrade	Evercore ISI	In-line → Outperform
Sep-04-18	Initiated	Citigroup	Buy
Aug-06-18	Downgrade	Goldman	Buy → Neutral
Jun-28-18	Initiated	Raymond James	Mkt Perform

View All

Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News

Feb 25, 2026

Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra’s Near US$1 Billion Debut Year - Yahoo Finance

Feb 25, 2026

Exit Recap: Will Madrigal Pharmaceuticals Inc outperform during market ralliesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn

Feb 25, 2026

Madrigal: The Easiest Money May Have Been Made (NASDAQ:MDGL) - Seeking Alpha

Feb 25, 2026

Feb 24, 2026

Madrigal Pharmaceuticals Reports 2025 Financial Results - MyChesCo

Feb 24, 2026

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times

Feb 24, 2026

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales - simplywall.st

Feb 23, 2026